Author | Melgaço, Fabiana Gil | |
Author | Azamor, Tamiris | |
Author | Villar, Livia Melo | |
Author | Bom, Ana Paula Dinis Ano | |
Author | Melgaço, Juliana Gil | |
Access date | 2022-02-06T12:50:54Z | |
Available date | 2022-02-06T12:50:54Z | |
Document date | 2021 | |
Citation | MELGAÇO, Fabiana Gil et al. Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case. Viruses, v. 13, 2143, p. 1-10, Oct. 2021. | pt_BR |
ISSN | 1999-4915 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/51039 | |
Language | eng | pt_BR |
Publisher | MDPI | pt_BR |
Rights | open access | |
Subject in Portuguese | COVID-19 | pt_BR |
Subject in Portuguese | SARS-CoV-2 | pt_BR |
Subject in Portuguese | Vacina | pt_BR |
Subject in Portuguese | Doença de Crohn | pt_BR |
Title | Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case | pt_BR |
Type | Article | |
DOI | 10.3390/v13112143 | |
Abstract | Vaccines to prevent the impact of SARS-CoV-2 are now available, including for patients with autoimmune diseases. However, there is no information about how inflammatory bowel disease (IBD) treatment could impact the cellular and humoral immune responses. This study evaluated SARS-CoV-2-specific humoral and cellular responses after vaccination with a two-dose schedule in a Crohn’s disease patient treated with Infliximab (10 mg/kg); we included comparisons with a monozygotic twin. The results showed that the Crohn’s disease’s twin (twin 2) had no antibody detection and reduced activation of CD4+ T cell responses, unlike the twin without the autoimmune disease (twin 1). Twin 2 developed antigen-specific central memory CD8+ T-cells and IFN production after the second dose of COVID-19 vaccination, similar to twin 1. These findings elucidated the role of T-cell immunity after COVID-19 immunization on IBD patients despite the lack of antibody production. Finally, our observation supports the consensus recommendation for IBD patients to receive COVID-19 vaccines. | pt_BR |
Affilliation | Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro. Laboratório de Cultu and s Biológicas. Duque de Caxias, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Crohn’s disease | pt_BR |
Subject | COVID-19 | pt_BR |
Subject | SARS-CoV-2 | pt_BR |
Subject | Vaccine | pt_BR |
xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |